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We previously reported that deficiency of membrane-type five matrix metalloproteinase
(MT5-MMP) prevents amyloid pathology in the cortex and hippocampus of 5xFAD
mice, and ameliorates the functional outcome. We have now investigated whether
the integrity of another important area affected in Alzheimer’s disease (AD), the
frontal cortex, was also preserved upon MT5-MMP deficiency in 4-month old mice
at prodromal stages of the pathology. We used the olfactory H-maze (OHM) to show
that learning impairment associated with dysfunctions of the frontal cortex in 5xFAD
was prevented in bigenic 5xFAD/MT5-MMP−/− mice. The latter exhibited concomitant
drastic reductions of amyloid beta peptide (Aβ) assemblies (soluble, oligomeric and
fibrillary) and its immediate precursor, C99. Simultaneously, astrocyte reactivity and
tumor necrosis factor alpha (TNF-α) levels were also lowered. Moreover, MT5-MMP
deficiency induced a decrease in N-terminal soluble fragments of amyloid precursor
protein (APP), including soluble APPα (sAPPα), sAPPβ and the MT5-MMP-linked
fragment of 95 kDa, sAPP95. However, the lack of MT5-MMP did not affect the activity
of β- and γ-secretases. In cultured HEKswe cells, transiently expressed MT5-MMP
localized to early endosomes and increased the content of APP and Aβ40 in these
organelles, as well as Aβ levels in cell supernatants. This is the first evidence that
the pro-amyloidogenic features of MT5-MMP lie, at least in part, on the ability of the
proteinase to promote trafficking into one of the amyloidogenic subcellular loci. Together,
our data further support the pathogenic role of MT5-MMP in AD and that its inhibition
improves the functional and pathological outcomes, in this case in the frontal cortex.
These data also support the idea that MT5-MMP could become a novel therapeutic
target in AD.
Keywords: matrix metalloproteinase, amyloid beta peptide, amyloid precursor protein, learning and memory,
endosomes, transgenic mice
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INTRODUCTION
Alzheimer’s disease (AD) is the most common
neurodegenerative disorder, characterized by progressive
cognitive decline, neuronal/synaptic loss and
neuroinflammation. The amyloidogenic hypothesis of the
disease postulates that excessive accumulation of amyloid beta
peptides (Aβ),—in synergy with tau hyperphosphorylation,—is
central to the pathogenic process (De Strooper, 2010; Selkoe
and Hardy, 2016). Aβ is produced by the sequential cleavage
of amyloid precursor protein (APP) by β-secretase (BACE-1)
and by the γ-secretase complex. APP processing produces
intermediate APP metabolites such as the β-secretase-derived
C-terminal APP fragment of 99 aminoacids (C99), which
is also neurotoxic (Lauritzen et al., 2012, 2016). Alternative
cleavage of APP by α-secretase (ADAM-10) prevents the
formation of Aβ and sets the basis for the non-amyloidogenic
pathway (Kuhn et al., 2010). While α-, β- and γ-secretases
constitute the classical enzymatic backbone of APP processing,
alternative APP processing enzymes are being discovered,
including δ- and η-secretases (Andrew et al., 2016). Early work
in cultured HEK cells showed that some membrane-type matrix
metalloproteinases (MT-MMPs) cleave APP at several sites
of the ectodomain (Ahmad et al., 2006). It has been recently
shown that the combined cleavage of APP by α-secretase
and MT5-MMP (putative η-secretase) at Asn504 and Met505
(APP695 numbering) generates a soluble fragment termed
Aη-α, which contains the N-terminal domain of Aβ and
displays synaptotoxic properties (Willem et al., 2015). We first
reported that APP processing by MT1-MMP and MT5-MMP
leads to an increase of Aβ levels in a heterologous cell system
(Py et al., 2014; Baranger et al., 2016b), and most important,
we demonstrated the contribution of MT5-MMP to AD
pathogenesis in the 5xFAD transgenic mouse model of AD
(Baranger et al., 2016b). MT5-MMP deficiency in these
mice substantially ameliorated their pathological outcome,
as illustrated by strong reductions in the neocortex and
hippocampus of Aβ and C99 levels, and neuroinflammation,
as well as the prevention of deficits in long-term potentiation
(LTP) and hippocampal-related spatial learning. Together, these
data unveiled MT5-MMP as a new relevant APP processing
enzyme with pro-amyloidogenic and synaptotoxic features that
contribute to AD pathogenesis.
We sought to extend our early findings on the role of
MT5-MMP in the 5xFAD model of the disease and evaluate the
impact of MT5-MMP deficiency on frontal cortex dysfunctions
characteristic of AD pathology. The frontal cortex controls
working memory and executive functions (Stuss and Alexander,
2000; Kane and Engle, 2002; Dalley et al., 2004), which
are deeply affected in Alzheimer’s patients at early stages
of the disease (Baddeley et al., 1991; Brugger et al., 1996;
Perry and Hodges, 1999). Accordingly, we have previously
shown that amyloidosis and gliosis correlate with behavior
disorders associated to the frontal cortex at early stages of
the pathology in 5xFAD mice (Girard et al., 2013). The
present study shows that MT5-MMP deficiency protects against
pathogenesis in the frontal cortex and prevents learning
and memory deficits in bigenic 5xFAD/MT5-MMP−/− mice
compared to 5xFAD. Moreover, MT5-MMP deficiency affects
APP processing andMT5-MMP expression promotes endosomal
trafficking of APP linked to increased amyloidogenesis in a
heterologous cell system. Overall, these data reinforce the idea
that MT5-MMP plays an important role in AD pathogenesis
and further highlight its interest as a potential therapeutic
target.
MATERIALS AND METHODS
Mice
The generation of bigenic 5xFAD/MT5-MMP−/− mice
(TgMT5−/− thereafter) has been thoroughly described elsewhere
(Baranger et al., 2016b). The 5xFAD mouse model of AD (Tg
thereafter; Oakley et al., 2006), 5xFAD/MT5-MMP−/−, MT5-
MMP−/− (MT5−/− thereafter, Komori et al., 2004) and
wild-type (WT) control mice, all in C57Bl6 background,
were bred in our animal facility. Mice had access to food
pellets and water ad libitum and were kept under a 12 h
light-dark cycle at 21◦C. Only 4-month old male mice
were used in this study. All experimental procedures were
approved by the ethics committee of the Faculty of Medicine
(Aix Marseille Université) in accordance with National and
European regulations (EU directive N◦2010/63), and in
agreement with the authorization for animal experimentation
attributed to the laboratory by the Prefecture des Bouches-
du-Rhône (permit number: D1305508). All efforts were made
to minimize animal suffering and to reduce the number of
mice used.
Behavioral Tests
Olfactory H-maze (OHM)
The olfactory H-maze (OHM) test was performed as previously
described (Del’Guidice et al., 2009; Girard et al., 2013). The
OHM is an entirely automated behavioral test designed to
investigate cognitive functions related to the frontal cortex
in mice such as spatial working memory and cognitive
plasticity. The OHM is based on the delayed reaction paradigm,
which is a specific marker of the frontal cortex function
in rodents and humans (Verin et al., 1993). Mice have to
discover in the H-shaped maze two different rules consecutively
(delayed alternation (ALT) and non-alternation task (N-ALT))
followed by a delayed reversal (REV) task. Mice under water
restriction have to learn in which end of the ‘‘H’’ (left or
right side of the testing chamber (TC)) they will obtain the
reward (a drop of water) according to three consecutive rules
(Figures 1A,B).
The OHM is composed of two identical TCs connected by
a straight plastic tube. Each TC is connected to two lateral
arms, which form altogether an H-shaped tubular structure
where mice can move freely (Figure 1A). At the extremity of
the lateral arms (E1–E4), water ports allow reward delivery.
Each group of two lateral extremities also delivers in an
alternating manner a synthetic odor. Thanks to an exhaust
fan located above each TC, this odor quickly reaches the
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FIGURE 1 | Cognitive abilities related to frontal cortex are preserved in TgMT5−/− mice. (A) Photograph showing a top view of the olfactory H-maze (OHM)
apparatus. Red arrows indicate the direction of the diffusing odor released by the extremities of the lateral arms E1 and E2 (and alternately E3 and E4) thanks to the
inverted exhaust fans placed above each testing chambers. (B) Schematic representation of the rule to learn on the alternation (ALT), non-alternation (N-ALT) and
reversal (REV) tasks. (C) Comparison of the mean percent of success (±SEM) across the 80 trials of each successive tasks (ALT, N-ALT, and REV) for the three
groups of mice (WT, Tg and TgMT5−/−). The number of successful mice out the total number of mice beginning the task is indicated inside each bar graph.
∗∗∗P < 0.001 between Tg and either WT or TgMT5−/− and ##P < 0.01 between TgMT5−/− and WT, ANOVA followed by post hoc Fisher’s LSD test. (D) Total
distance traveled in the open-field test during the two successive blocks of 5 min and during cumulated 10-min session. (E) Percentage of time spent by mice in the
center of the open field. In (D,E), values are the mean ± SEM of 12 mice per genotype. ∗P < 0.05, ∗∗P < 0.01, ANOVA followed by post hoc Fisher’s LSD test.
TC before being rapidly ejected into the room, which is also
equipped with an exhaust ventilation system. The scented air
guides mice to the TC where the reward is delivered, but
only one side of this TC is associated with the reward. Mice
movements are detected by photoelectric cells that generate
an infrared beam. When mice interfere with the beam, this
triggers water delivery or not, depending on the extremity and
the rule.
Odor and water delivery were controlled by a microcomputer
running with LabVIEW software (National Instruments France)
that also recorded the behavioral data. The experiments were
performed in the dark. The experimenter and the computerized
recording system were located in an adjacent room and mice
observed under infrared camera. The learning procedure was
composed of four habituation days followed by one testing day.
During the first 4 days mice are habituated to the experimenter
and to the maze. Mice placed under water restriction have access
to water every habituation day in the extremities of the maze
lateral arms in the presence of the odor. The testing session
consists in discovering the three consecutive tasks: ALT, N-ALT
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and REV. From a previous study (Belhaoues et al., 2005), the
success criterion was set at four consecutive correct trials and
then the rule switched automatically. The session ended when
the rules of three successive tasks were discovered. Mice that
did not succeed within the limits of either 1 h-trial or 80 trials
were excluded from the study and did not continue on the
following tasks. Mice performance was compared using themean
percentage of success, which was obtained with the sum of
cumulated percentage of success divided by eighty, themaximum
number of trials for each task (see for details, Girard et al.,
2013).
Open Field Test
The open field test was used to assess spontaneous locomotor
activity and exploratory behavior in the same mice that
performed the OHM. The open field was a white plastic
square of 50 cm on each side and walls 45 cm high. Testing
was carried out in a dimly illuminated room (40 lux) and
recorded by an automated tracking system using a video
camera mounted above the apparatus (Viewpoint VideoTrack
version 3.0, Champagne Au Mont D’or, France). Animals were
placed in the center of the field and the traveled distance
measured in one 10-min session. In order to identify a possible
heterogeneity in mice behavior across time, we analyzed the
average scores in each of the 5-min intervals as well as the
average of the entire 10-min session. Moreover, we measured
the percentage of time spent by mice in the center of the arena
(20 cm× 20 cm) with respect to the total time following the same
time intervals as above. The square was cleaned at the end of each
session.
Immunohistochemistry, Image Analysis
and Quantifications
Mice were deeply anesthetized with an intraperitoneal injection
of 355 mg/kg sodium pentobarbital (Ceva Santé Animal,
Libourne, France) and transcardially perfused with cold saline
solution (NaCl 0.9%), followed by fixation with Antigenfix
solution (Diapath, MM France, Brignais, France). Brains
were then post-fixed 24 h in the same fixative and stored
(4◦C) in phosphate buffer saline (PBS), pH 7.4. Free-floating
coronal sections (30 µm thick) were obtained using a
vibratome (Microm HM 650V, Thermo Scientific, MA, USA)
and stored at −20◦C in a cryoprotectant solution (30%
glycerol, 30% ethylene glycol, 30% ultra-pure water and
10% of 0.2M PBS). Sections were pre-incubated in a blocking
solution (PBS, 3% BSA and 0.1% Triton X-100), followed
by overnight incubation at 4◦C with anti-GFAP (1/300,
Dako France, Trappes, France), anti-Iba1 (1/300, Wako,
Sobioda, Montbonnot-Saint-Martin, France), anti-Aβ 6E10
(1/300, Ozyme, Saint Quentin en Yvelines, France), and the
corresponding secondary anti-rabbit or anti-mouse antibodies
coupled to Alexa Fluorr 488 and 568 (Life Technologies,
Saint Aubin, France) for 3 h at room temperature. Nuclei
were stained with 0.5 µg/mL DNA intercalant Hoechst #33258
(Life Technologies). Sections were mounted using Prolong
Gold Antifade reagent (Life Technologies). Negative control
immunostaining was performed without the primary antibody,
and no immunoreactivity was confirmed. Samples were observed
under a LSM 700 confocal or Axiovert inverted microscope
(Zeiss, Jena, Germany). Images were analyzed using the
Axiovision (Zeiss), Photoshop (Adobe) and ImageJ (NIH)
softwares.
The number of plaques was blindly scored in two brain
sections per animal by three investigators at bregma 2.68 and
2.46 and normalized by the surface of the brain region
analyzed. The average area of individual plaques was measured
using the analyze particles plugin from Image J. ‘‘Dense
core plaques’’ were identified as having a compact spherical
appearance without scattered amyloid granules/fibrillar-like
structures around, whereas ‘‘diffuse plaques’’ exhibited a halo
of granular/fibrillar-like structures around a center area where
a compact amyloid core was or was not present. Images
of immunostaining for glial markers were acquired using
identical exposure times and settings across the different groups.
Background was substracted from these images using the Image J
rolling ball radius algorithm. The same fluorescence threshold
and binarization settings were applied to all images before
measuring the immunostained area over the total area.
Western Blot Biochemical Analysis
The detection of APP fragments in different fractions was
carried as previously described with, slight modifications
(Baranger et al., 2016b). To detect the soluble forms sAPPα
and sAPPβ, male mice were deeply anesthetized as indicated
above and transcardially perfused with cold saline solution
(NaCl 0.9%). The frontal cortex was microdissected and
snap-frozen with cold isopentane for biochemical assays. To
obtain insoluble and soluble dyethylamine (DEA)-extracted
fractions, frozen tissue was homogenized in 500 µL of
cold DEA buffer (50 mM NaCl, 2 mM EDTA, 0.2% DEA,
proteinase inhibitor cocktail (Millipore) with a rotor-stator
homogenizer, directly followed by neutralization of the
homogenate with Tris-HCl buffer, pH 6.7. Homogenate
was centrifuged at 5000 r.p.m. for 5 min. Supernatants
were transferred to new vials and subjected to clarifying
ultracentrifugation at 55,000 r.p.m. for 30 min using a
TLA55 rotor. Pellets were washed with PBS to remove the
remaining soluble fraction and then lysed in STE buffer
(150 mM NaCl, 50 mM Tris-HCl, 2 mM EDTA) and 1%
Triton for 60 min on ice followed by centrifugation at
14,000 r.p.m for 10 min at 4◦C. The resulting insoluble
fractions were transferred to fresh tubes. Protein concentration
of insoluble or DEA fractions was measured using the Bradford
(BCA) method according to the manufacturer’s instructions
(Interchim, Mannheim, Germany). Proteins were separated
on 10% SDS-PAGE gels, and then transferred to a 0.45 mm
nitrocellulose membrane (Whatmanr, Maidstone, Kent, UK).
After blocking, membranes were probed with the following
primary antibodies: anti-APP N-ter, clone 22C11 (1/1000,
Millipore), anti-APP C-Ter, clone 2C11; anti-mAPPs-α,
clone 7A6; anti-hAPPs-α, clone 14D6; anti-APPs-β wt, clone
192 wt and anti-hAPPs-β swe, clone 192 swe (both kindly
provided by Dale Schenk) and anti-β-actin (Sigma-Aldrich,
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Saint Quentin-Fallavier, France). Blots were developed using
appropriate horseradish peroxidase-conjugated secondary
IgG antibodies (Promega Corp., Madison, WI, USA and
anti-rat HRP, Santa Cruz Biotechnology Inc., Dallas, TX, USA)
and the ECL chemiluminescence system (GE Healthcare).
Quantification of western blots was performed using Fuji
Las-4000 software (Fuji Film inc., Minato, Tokyo, Japan) and
Image J.
For the analysis of 6E10+ and N-cadherin fragments,
GFAP, PSD-95, synaptophysin and β-III tubulin, male mice
were anesthetized and brains dissected as indicated above.
Samples were homogenized in 25% w/v of 50 mM Tris-
HCl, pH 7.5 buffer containing 150 mM NaCl, 2 mM EDTA,
1% Triton X-100, 0.05% SDS and proteinase inhibitor cocktail
(Millipore) and centrifuged at 10000× g for 10 min at 4◦C.
This ‘‘soluble fraction’’ contained cytosolic proteins and
proteins easy to solubilize. Cell pellets were resuspended
in 25% w/v of 50 mM Tris-HCl pH 7.5 buffer containing
2% SDS, then sonicated and centrifuged at 10000× g for
10 min at 4◦C to obtain an ‘‘insoluble fraction’’ containing
more insoluble proteins, among which an important
part of membrane proteins (Reinés et al., 2012). Protein
concentrations were determined using a Bio-Rad DCTM
protein assay kit (Bio-Rad, Marnes-La-Coquette, France) and
50 µg of protein were run on 10%–15% SDS-PAGE gels
and transferred to nitrocellulose membranes (Amersham
Bioscience, Velizy-Villacoublay, France; Py et al., 2014).
After blocking, membranes were probed with the following
antibodies: anti-GFAP (1/1000, Millipore), anti-Aβ 6E10
(1/300, Ozyme), anti-APP C-terminal fragment (APP-CTF,
1/2000, Sigma-Aldrich), anti-N-cadherin CTF (1/1000, BD
Biosciences, Le Pont de Claix, France), anti-PSD-95 (1/2000,
Millipore), anti-synaptophysin (1/2000, Millipore), anti-β-
III tubulin (1/3000, Sigma-Aldrich), anti-GAPDH (1/5000,
Millipore) and anti-β-actin (1/5000, Sigma-Aldrich), and then
incubated with appropriate horseradish peroxidase-conjugated
secondary IgG antibodies (Jackson Immunoresearch, West
Grove, PA, USA). Immunoblot signals were visualized
using the ECL chemiluminescence kit (GE Healthcare,
Dutscher, Brumath, France) and quantified using ImageJ
software.
For the detection of APP CTF CTFα and CTFβ, respectively
derived from APP processing by α- and β-secretases, PS1 and
nicastrin, solubilized membranes were used as reported
previously (Sevalle et al., 2009; Baranger et al., 2016b). Briefly,
frontal cortex samples were resuspended in 10 mM Tris–HCl
buffer, pH 7.5 with proteinase inhibitors (Sigma-Aldrich),
subjected to repeated passages through a 25G needle and
first centrifuged at 800× g for 10 min at 4◦C. The resulting
supernatants were centrifuged at 20,000× g centrifugation
for 1 h at 4◦C. Pellets containing the membranes were then
resuspended in solubilization buffer, 150 mM sodium citrate, pH
6.4 with 3-[(3-cholamidopropyl) dimethylammonio]-2-hydroxy-
1-propanesulfonate (CHAPSO, 1% (v/v)) and proteinase
inhibitors (Millipore). Samples were diluted in solubilization
buffer at (1 mg/mL). The denatured samples were analyzed by
western blot using APP-CTF (1/2000, Sigma-Aldrich), anti-PS1
N-terminal (1/1000, provided by Paul Fraser), and anti-nicastrin
(1/1000, Sigma-Aldrich) antibodies, and normalized using an
anti-tubulin antibody (1/5000, Sigma-Aldrich).
BACE-1 Activity Assay
To assess β-secretase activity, 15 µg of proteins from solubilized
membranes were used as previously described (Andrau et al.,
2003). Briefly, samples were incubated in a final volume of acetate
buffer (25 mM, pH 4.5, 100 µL) containing 10 µM of BACE-1
substrate (7-methoxycoumarin-4-yl)-acetyl-SEVNLDAEFRK(2,
4-dinitrophenyl)-RRNH2 (R&D Systems, Bio-Techne, Lille,
France) with or without β-secretase inhibitor I (75 µM;
PromoCell, Heidelberg, Germany). BACE-1 activity corresponds
to the β-secretase inhibitor I-sensitive fluorescence recorded at
320 (excitation) and 420 (emission) nm wavelengths, using a
FLUOstar Omega spectrofluorometer (BMG Labtech, Palaiseau,
France).
Plasmid Construction
The MT5-MMP cDNA was amplified by PCR from
C57Bl6 mouse cerebellum, and cloned as described earlier
for other MMPs (Sbai et al., 2008; Ould-Yahoui et al., 2009;
Sbai et al., 2010). We used the following primers: MT5For ATA
TAT GAA TTC GGA TGC CGA GGA GCC GGG GAG GCC
GCG CTG and MT5Rev ATA TAT GTC GAC AGT ACC CAC
TCC TGG ACC GGC CGC TTA TAG TAG and cloned into
pEGFP-N1 (Clontech, Saint-Germain-en-Laye, France). This
cDNA construct is referred to as MT5. Green fluorescent protein
(GFP) and MT5 plasmids were amplified in DH5α E. coli (Life
Technologies) and purified using the NucleoBond Xtra Midi
Plus EF (Macherey-Nagel, Hoerd, France) according to the
manufacturer’s recommendations.
Transferrin Pulse Chase and Colocalization
of APP/Aβ in the Endosomal System
The impact of MT5-MMP on APP intracellular trafficking was
studied on HEKswe cells stably transfected with pcDNA3 coding
for human APP harboring the Swedish mutation (Marambaud
et al., 1998). To perform immunocytochemistry, 6.104 cells/well
were plated on coverslips for 24 h and then transfected with
a plasmid coding for MT5-MMP (MT5) fused to GFP in the
C-terminal end. GFP plasmids were used as controls (Baranger
et al., 2016b). Endosomes were labeled with 0.25 mg/mL Alexa
Fluorr 647-transferrin (Tf; Life Technologies) for 30 min, which
mostly labels early endosomes in HEK cells (Kaether et al.,
2006a). Cells were then fixed for 15 min at room temperature
with Antigenfix solution (Diapath) and incubated for 1 h
at room temperature in a PBS blocking solution containing
0.1% Triton X-100 and 3% BSA. Cells were then incubated
overnight at 4◦C with anti-Aβ 6E10 (1/300, Ozyme) and
anti-GFP (Millipore) antibodies. Endosomes were labeled using
antibodies against anti-EEA1 (Early Endosome Antigen 1,
1/300, Santa-Cruz Biotechnology, Heidelberg, Germany),
anti-Rab11 (1/300, BD Biosciences) and anti-Rab7 (1/300,
Abcam, France) to respectively label early, recycling and late
endosomes/lysosomes. Anti-Aβ40 antibody (Ozyme) was used
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to specifically recognize the genuine Aβ40 C-terminal end
generated after γ-secretase cleavage. The coverslips were rinsed
in PBS 1X and then incubated with the appropriate Alexa
Fluorr-conjugated secondary antibodies (Life Technologies)
for 1 h at room temperature. Nuclei were stained with Hoechst
#33258 for 10 min (0.5 µg/mL, Life Technologies). Omission
of the primary antibody was used as negative control and no
immunostaining was observed. Coverslips were mounted using
Prolong Gold Antifading reagent on Superfrost glass slides (Life
Technologies).
Images were taken and processed using a confocal microscope
(LSM 700) and Zen software (Zeiss). Between five and seven
stacks of 0.4 µm per cell were generated and colocalization
measured in each single stack using the Jacop plugin of ImageJ
(Bolte and Cordelieres, 2006). We analyzed at least 20 cells
per group and per independent experiment. To analyze the
impact of the proteins expressed following transfection on
APP/Aβ content, we quantified the percentage of colocalization
between Aβ 6E10 and Alexa Fluorr 647-Tf, and colocalization
between Aβ40 and, EEA1, Rab11 and Rab7. We also performed
a qualitative analysis of MT5-MMP/GFP distribution in
endosomal vesicles labeled by Alexa Fluorr 647-Tf. Finally,
we evaluated possible changes in the content of endosomes by
measuring the cell area occupied by Alexa Fluorr 647-Tf in each
experimental condition relative to the total cell area.
ELISA Assays
For detection of Aβ38, Aβ40 and Aβ42 in the DEA fractions
from the frontal cortex, we used the MSD Aβ Triplex sandwich
immunoassay (MesoScale Discovery, Rockville, MD, USA).
MSD C-terminal-specific antibodies were pre-spotted into each
well. For detection, a ruthenylated 6E10 antibody was used.
The concentrations of human Aβ peptides were normalized
to protein content and calculated using the MSD Discovery
Workbench software. For detection of Aβ40 levels in cell
supernatants of HEKswe cells, the human Aβ40 ELISA kit
(Life Technologies) was used according to the manufacturer’s
recommendations. The γ-secretase inhibitor DAPT (Tocris,
Bio-Techne, Lille, France), 10 µM for 48 h, was used to
inhibit Aβ production. The levels of proinflammatory mediators
interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α) and
monocyte chemoattractant protein-1 (MCP-1) in triton-soluble
fractions were determined using the murine ELISADevelopment
Kit (Peprotech, Neuilly-sur-Seine, France) according to the
manufacturer’s recommendations.
Statistics
Significant differences between groups were determined
by a one-way ANOVA followed by post hoc Fisher’s LSD
for multiple comparisons. Two-tailed unpaired Student
t-tests were used to compare two experimental groups.
The analysis of OHM data was performed using repeated-
measures (MANOVA) across the entire session and then
by one-way ANOVA for each task followed by post hoc
Fisher’s LSD for multiple comparisons. In all cases we
used the Kaleida Graph software. Values represent the
means ± SEM of the indicated number of independent
experiments/animals, and the level of significance was set at
P < 0.05.
RESULTS
MT5-MMP Deficiency in 5xFAD Mice
Prevents Learning Deficits in the Olfactory
H-maze Task without Alterations of
Locomotion
The comparison of the mean percentage of success on 80 trials
across the three groups (WT, Tg and TgMT5−/−) of 4-month
old male mice (Figure 1C) revealed a substantial difference
between Tg and the WT and TgMT5−/− mice in their ability to
perform the three successive tasks (MANOVA Task × Group
interaction: F(2,237) = 32.97; P < 0.001), with a significant
group difference (MANOVA: F(2,237) = 8.35; P < 0.001).
All the groups scored a similar mean percentage of success
in the first task (ALT; ANOVA: F(2,237) = 0.35; ns), but a
significant difference was observed in the N-ALT and REV
tasks (ANOVAs: F(2,237) ≥ 19.39; P < 0.001). Indeed, analysis
of the N-ALT and REV tasks revealed that Tg mice displayed
significantly lower levels of performance on these two tasks
compared to WT and TgMT5−/− (Figure 1C). In addition,
a significant difference was also observed between WT and
TgMT5−/− on the last task (REV; Figure 1C). It has to be
noted that on the N-ALT task, two Tg mice failed to solve
the task, while all the WT and TgMT5−/− were successful.
On the REV task, four more Tg mice and four WT failed
to meet the criterion, while only one TgMT5−/− did not
reach the criterion. All the mice were submitted to the
open-field paradigm (Figure 1D). The three groups of mice
showed similar locomotor activity during the 10-min session
(ANOVAs: F(2,33) ≤ 1.84; ns; Figure 1D), indicating that
the differences observed in the OHM were not the result of
altered locomotor activity. However, Tg mice spent more time
in the center of the arena than WT mice (ANOVAs: F(2,33)
≥ 3.29; P < 0.05), suggesting that Tg mice were less anxious.
TgMT5−/− mice scores were between WT and Tg values and
showed no statistical differences with respect to either group
(Figure 1E).
Decreased Aβ Plaques and
Neuroinflammatory Response in the
Frontal Cortex Of TgMT5−/− Mice
In agreement with our previous description of the 5xFAD
model (Girard et al., 2013), amyloid plaques were abundant
in the frontal cortex at 4 months of age. This is illustrated in
Figure 2 by immunohistochemistry with the 6E10 antibody,
which recognizes the N-terminal domain of the human Aβ
sequence. Compared to Tg, TgMT5−/− mice exhibited a 75%
significant decrease in the number of plaques (Figures 2A,B),
which were smaller in average (323 ± 57 µm2) compared
to Tg (519 ± 122 µm2), although it did not reach statistical
significance. Moreover, 66.3% of plaques in Tg brains had a
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FIGURE 2 | Decreased amyloid burden and neuroinflammation in the frontal cortex of TgMT5−/− mice compared to Tg. (A) Representative
epifluorescence microphotographs showing a strong decrease of 6E10 and GFAP immunostaining in coronal sections of frontal cortex from TgMT5−/−, compared
Tg mice; scale bar 100 µm. Insets represent high power magnification from selected fields; scale bar 20 µm. (B) Quantification of the number of plaques over the
area of frontal cortex in Tg and TgMT5−/− mice. Values are the mean ± SEM of 5–6 brains per genotype. ∗∗P < 0.01; Student’s t test. (C) Quantification of the
percentage of dense core and diffuse plaques over the total measured area of frontal cortex in Tg and TgMT5−/− mice. On the right, representative epifluorescence
microphotographs of both plaque phenotypes stained with the 6E10 antibody (arrowheads). Values are the mean ± SEM of 5–6 brains per genotype. ∗∗P < 0.01;
Student’s t test; ns, non significant. (D) Quantification of changes in GFAP immunostaining as the percentage of the immunostained area/total area in the frontal
cortex. Values are the mean ± SEM of 5–6 brains per genotype. ∗∗P < 0.01, Student’s t test. (E) Representative western blot (left) and the corresponding
quantification (right) in arbitrary units (A.U.), showing GFAP immunoreactivity in the soluble fraction of frontal cortices from Tg and TgMT5−/− mice. Values are the
mean ± SEM of 5–6 brains per genotype. ∗P < 0.05, Student’s t test. (F) ELISA assay showing quantification of IL-1β, MCP-1 and TNF-α levels (pg/µg of protein) in
the soluble fraction of frontal cortices from WT, Tg and TgMT5−/− mice. Values are the mean ± SEM of 5–6 mice per genotype. ∗P < 0.05, ANOVA followed by
post hoc Fisher’s LSD test.
diffuse phenotype with or without a dense core inside, while
only the remaining 33.7% presented an amyloid dense core
without surrounding deposits. These statistically significant
differences found in Tg mice disappeared in the frontal cortex
of TgMT5−/− mice, with a 53.7%/46.3% diffuse vs. dense ratio
(Figure 2C).
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Reduction of amyloid burden in the frontal cortex of
TgMT5−/− mice was concomitant with a strong 81% reduction
in astroglial reactivity, as demonstrated by quantification of
GFAP immunostaining (Figure 2D), further confirmed by a 50%
decrease in GFAP levels measured by western blot (Figure 2E).
No significant differences were observed in microglial reactivity
evaluated with an Iba1 antibody (not shown). Seemingly the
levels of two pro-inflammatory mediators commonly associated
with Alzheimer’s pathology, IL-1β and MCP-1 remained stable
between WT, Tg and TgMT5−/− mice, although a tendency
to decrease in TgMT5−/− tissue was observed (Figure 2F). In
contrast with IL-1β and MCP-1, TNF-α levels increased by 33%
in Tg with respect to WT mice, and most interestingly, such
increase was not detected in TgMT5−/− mice (Figure 2F).
Unchanged Levels of Markers of Neuronal
and Synaptic Integrity
Dysfunctional synaptic plasticity correlates well with learning
deficits in AD (Selkoe, 2008). In addition, it has been suggested
that MT5-MMP could work in synergy with γ-secretase to
disrupt synaptic integrity and hence synaptic transmission
(Restituito et al., 2011). Accordingly, we examined whether
the integrity of synapses or the neuronal network could be
compromised in the frontal cortex of Tg mice with impaired
learning, and improved by the lack of MT5-MMP. The
pre-synaptic marker synaptophysin and neuronal specific
marker β-III tubulin were equally distributed across WT, Tg
or TgMT5−/− genotypes in the triton-soluble (Figure 3) or
insoluble (not shown) fractions. The post-synaptic marker
PSD-95 was mainly detected in the insoluble fraction
(Figure 3) and its levels remained also stable across genotypes,
indicating altogether that the structure of the neuronal network
was relatively well preserved at the 4-month stage of the
pathology.
Decreased Levels of Soluble Aβ, and
Various N-terminal and C-terminal APP
Fragments in the Frontal Cortex of
TgMT5−/− Mice
The striking decrease in the content of amyloid plaques upon
MT5-MMP deficiency paralleled similar reductions in the levels
of soluble Aβ species, including Aβ38 (−83%), Aβ40 (−84%)
and Aβ42 (−90%; Figure 4A). We also detected significant
reductions of ∼12 and ∼15 kDa 6E10+ bands in frontal
cortex homogenates of TgMT5−/− mice compared to Tg
(Figure 4B). The sizes of these bands are compatible with
the expected size for Aβ trimers or Aη-α and βCTF C99,
respectively.
Further changes in APP metabolism were detected when
analyzing the levels of soluble APP (sAPP) in DEA soluble
fractions (Figures 4C,D); the 22C11 antibody, which recognizes
the N-terminal domain of APP, revealed a ∼110 kDa band that
was respectively upregulated in Tg and TgMT5−/− brains by
2.73- and 2.05-fold, compared to WT, while no differences were
observed between Tg and TgMT5−/− (Figures 4C,D). A lower
band of ∼95 kDa (sAPP95) was also significantly upregulated
by 4.2-fold in Tg frontal cortex with respect to WT. The
sAPP95 fragment was not detected with the 6E10 or APP-CTF
antibodies (not shown). However, sAPP95 levels dropped by 49%
in TgMT5−/− frontal cortices with respect to Tg, but were still
2.1-fold above WT values (Figures 4C,D). Consequently, the
FIGURE 3 | The levels of synaptic and neuronal markers are not affected in the frontal cortex of TgMT5−/− mice. Representative western blots for
synaptophysin and β-III tubulin (soluble fraction) and PSD-95 (insoluble fraction) of frontal cortices from WT, Tg and TgMT5−/− mice. The actin-normalized values
show no differences between the three genotypes. Values are the mean ± SEM of 5–6 mice per genotype. ANOVA followed by post hoc Fisher’s LSD test. Vertical
dashed lines on western blots separate non-contiguous bands from the same gel.
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FIGURE 4 | Amyloid precursor protein (APP) metabolism is reduced in the frontal cortex of TgMT5−/− mice compared to Tg. (A) ELISA quantification
(pg/mg protein) of Aβ38, Aβ40 and Aβ42 levels in DEA fractions. Values are the mean ± SEM of 5–6 mice per genotype. ∗P < 0.05, ∗∗P < 0.01, Student’s t test.
(B) Representative western blots (left) showing 6E10+ immunoreactivity in the insoluble fraction of the frontal cortex. The lower western blot has been highly exposed
to highlight the decrease of βCTFs and the ∼12 kDa band in TgMT5−/− compared to Tg mice, and the appearance of diffuse immunoreactivity in Tg samples below
around 6 kDa. The plots (right)
(Continued)
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FIGURE 4 | Continued
show the corresponding quantifications for the βCTFs and the ∼12 kDa band.
Values are the mean ± SEM of 5–6 actin-normalized optical densities (OD);
A.U., arbitrary units. ∗P < 0.05, ∗∗∗P < 0.001, Student’s t test. (C) Western
blot showing full length (fl) APP in the soluble (22C11 antibody) and insoluble
(2C11 antibody) fractions. Note that the levels of a soluble 95 kDa short form
of APP (sAPP95) are downregulated in TgMT5−/− brains compared to Tg.
(D) The corresponding quantification of APP levels in the soluble fraction of
frontal cortex from WT, Tg and TgMT5−/− mice, using the 22C11 (N-ter) and
2C11 (C-ter) antibodies. Actin-normalized values are the mean ± SEM of
5–6 mice per genotype. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 between Tg and
either WT or TgMT5−/−; #P < 0.05, ##P < 0.01 between TgMT5−/− and WT,
ANOVA followed by post hoc Fisher’s LSD test. Vertical dashed lines on
western blots separate non-contiguous bands from the same gel.
sAPP/sAPP95 ratio in WT and TgMT5−/− tissues was 1.5-fold
higher than in Tg (Figure 4D). APP levels in the insoluble
fraction were measured using the APP C-terminal antibody
2C11, which detected a ∼130 kDa band likely representing the
canonical protein (full-length, fl; Figure 4C). Consistent with the
presence of an additional copy of humanAPP in transgenic mice,
higher levels of flAPP were detected in the frontal cortex of Tg
(2.3-fold) and TgMT5−/− (2-fold)mice compared toWT, and no
significant differences were observed between Tg and TgMT5−/−
(Figure 4D).
The data above suggested that MT5-MMP deficiency could
affect APP processing N-terminally and therefore impact on
the generation of sAPPα and sAPPβ, the soluble N-terminal
fragments released by α- and β-secretase, respectively. Thus
sAPPα and sAPPβ levels can be considered as an indirect
readout of the activity of these secretases (Kuhn et al., 2010).
Accordingly, we used the 14D6 and 192swe antibodies, which
specifically recognize the C-terminal neoepitopes of sAPPα and
sAPPβ (Figure 5A). The levels of sAPPα and sAPPβ respectively
augmented by 5.7- and 11.2-fold in Tg compared to WT.
Such increases were strongly attenuated in the frontal cortex
of TgMT5−/− mice, whose levels significantly dropped 58.5%
(sAPPα) and 54% (sAPPβ) compared to Tg, and nearly reached
statistical significance with respect to WT values (P = 0.058 for
sAPPα; P = 0.057 for sAPPβ; Figure 5A).
We used an APP-CTF antibody to assess the impact of
the genotype on the levels of the remaining membrane bound
C-terminal APP fragments, after cleavage by α- and β-secretase
cleavage (Figure 5B). Thus, we detected inWT samples a doublet
of∼15 kDa representing C83 and much less abundant C99. Both
C83 and C99 were largely upregulated in Tg brains, 2.4-fold
for C83 and 9.1-fold for C99. Most important, C99 levels were
strongly reduced by 61.7% in TgMT5−/−, compared to Tg mice,
but were still significantly higher (4-fold) than WT levels. In
contrast, C83 levels were not reduced in TgMT5−/− compared
to Tg samples and remained significantly upregulated by 2-fold
with respect to WT (Figure 5B).
Preserved β- and γ-secretase Activity in
the Frontal Cortex of TgMT5−/− Mice
The observed reduction of sAPPβ levels in TgMT5−/− could
reflect a deficit of β-secretase activity, which could ultimately
contribute to the anti-amyloidogenic effects of MT5-MMP
deficiency. We further investigated this contingency using an
enzymatic assay for BACE-1 activity (Andrau et al., 2003), the
main β-secretase that catalyzes the rate-limiting step for Aβ
production. The in vitro test on homogenates from WT, Tg
and TgMT5−/− frontal cortices did not detect any genotype-
associated alteration of BACE-1 processing a specific fluorogenic
substrate over a 6 h-time period (Figure 6A).
To determine whether changes in the content of C99 were
related with alterations of γ-secretase activity per se, we
leveraged on the autocatalytic activity of PS1, the main
proteolytic unit of the γ-secretase complex. We detected
by western blot the ∼55 kDa full-length form and a
∼30 kDa N-terminal fragment (NTF-PS1) resulting from
PS1 autocatalysis (Figure 6B). As anticipated, transgenic mice
carrying an additional copy of the mutated human PSEN1
gene exhibited higher levels of PS1 compared to WT, but
there were no differences in processed NTF-PS1 content,
indicating similar γ-secretase-mediated endoproteolysis activity
in Tg and TgMT5−/− mice (Figure 6B). Seemingly, there
was no difference between genotypes in the content of
nicastrin, another member of the γ-secretase complex necessary
for substrate recognition. This is illustrated in Figure 6C,
which shows no changes in the immature and mature forms
of nicastrin, respectively associated with pre-assembled and
assembled γ-secretase complex, suggesting altogether that the
enzymatic complex is intact (Figure 6C). The finding that
another γ-secretase substrate, the 37 kDa C-terminal domain
of N-cadherin, was similarly processed across genotypes,
further supported a genotype-independent catalytic activity of
γ-secretase (Figure 6D).
MT5-MMP Modulates the Content of
APP-derived Species in the Endosomal
System
The above data pose an intriguing scenario where decreases
in N-terminal and C-terminal APP fragments would not be
necessarily linked to changes in β- and γ-secretase activities.
One possibility is that MT5-MMP affects the intracellular
distribution/trafficking of APP, as previously hypothesized
(Baranger et al., 2016a). To test this idea, we overexpressed
MT5-MMP in HEKswe cells that express an APP with the
Swedish mutation also present in 5xFAD mice, and that have
been previously used as a cell model to study APP trafficking
(Kaether et al., 2006b). Following transient transfection of the
MT5-MMP/GFP (MT5) fusion protein in HEKswe cells, we
combined 6E10+ immunostaining and Alexa Fluorr 647-Tf
pulse labeling for 30 min. In these conditions, Tf mainly
labels early endosomes, considered as important loci of β- and
γ-secretase activity, and hence of Aβ production (Rajendran and
Annaert, 2012; Wang et al., 2014). MT5 expression decreased the
levels of 6E10 immunoreactivity in HEKswe cells (Figures 7A,C).
On the contrary, 6E10 colocalization with Tf in MT5 expressing
cells increased by 82%, compared to GFP (Figures 7A,B).
MT5 expression did not modify the content of endosomes
with respect to GFP transfected cells (Figures 7A,D). Clearly,
MT5 partially colocalized with early endosomes, as revealed by
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FIGURE 5 | sAPPα, sAPPβ and C99 levels are strongly decreased in the frontal cortex of TgMT5−/− mice compared to Tg. (A) Western blot analysis (left)
and quantification (right) of APP levels using specific antibodies against human sAPPα (14D6) and sAPPβ (192swe) that recognize the neoepitopes generated after
α- or β-secretase cleavage. Note that the increase observed in Tg mice was prevented by MT5-MMP deficiency in TgMT5−/− mice. Actin-normalized values are the
mean ± SEM of 5–6 mice per genotype. ∗P < 0.05, ∗∗∗P < 0.001, ANOVA followed by post hoc Fisher’s LSD test. OD, optical density; A.U., arbitrary units.
(B) Western blot analysis (left) and quantification (right) of APP C-terminal fragment (CTF) C99 and C83 in solubilized membranes using the CTF-APP antibody, which
recognizes the C-terminal end of APP. Tubulin-normalized values are the mean ± SEM of 5–6 mice per genotype. OD, optical density; A.U., arbitrary units ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001 between Tg and either WT or TgMT5−/− and #P < 0.05, ##P < 0.01 between TgMT5−/− and WT, ANOVA followed by post hoc Fisher’s
LSD test. Vertical dashed lines on western blots separate non-contiguous bands from the same gel.
double immunofluorescence with anti-GFP antibody and Alexa
Fluorr 647-Tf (Figure 7E).
It is plausible that 6E10 immunostaining in endosomes
mainly reflects a pool of C99 and Aβ40, the latter being largely
the predominant Aβ species generated in HEKswe cells (Buggia-
Prevot et al., 2008). To further identify the distribution of the
Aβ40 pool we combined antibodies that recognize the genuine
C-terminal end of Aβ40 after C99 processing by γ-secretase, and
antibodies against EEA1, Rab11 and Rab7, which are markers
of early, recycling and late endosomes, respectively (Figure 7F).
MT5 induced a significant 57% increase of Aβ40 colocalization
with EEA1 compared to controls, and had no effect on Rab11 or
Rab7. Moreover, the supernatants of MT5-transfected cells
exhibited a 75% increase of Aβ40 levels, which was prevented by
the γ-secretase inhibitor DAPT (Figure 7G).
DISCUSSION
MT5-MMP is the only member of the MMP family
predominantly expressed in the nervous system. Early work
highlighted its role in peripheral nervous system (PNS)
neuroinflammation (Folgueras et al., 2009), and neuropathic
pain after spinal cord lesion (Komori et al., 2004). More
recently we demonstrated that MT5-MMP deficiency in the
5xFAD mouse model of AD remarkably ameliorated the
outcome of the pathology affecting neocortical and hippocampal
functions (Baranger et al., 2016b). The present study extends
these data and reveals that MT5-MMP deficiency is also
beneficial in the frontal cortex of 5xFAD mice. Thus, preserved
memory consistently correlated with a strong reduction
of Aβ load, astroglial reactivity and TNF-α levels. Our
study also reveals that MT5-MMP deficiency prevented the
increase in the levels of soluble N-terminal APP fragments
and the neurotoxic transmembrane C99 observed in the
frontal cortex of Tg mice. Changes in APP processing
in TgMT5−/− mice occurred in the absence of intrinsic
proteolytic dysfunctions of β- and γ-secretases. Finally,
our data provide evidence that the distribution of APP/Aβ
in the endosomal system is altered upon modulation of
MT5-MMP expression in a heterologous system, suggesting
a new possible mechanism whereby MT5-MMP could drive
APP trafficking and its metabolism towards the amyloidogenic
pathway.
MT5-MMP Deficiency Prevents Cognitive
Deficits Associated with Frontal Cortex
Dysfunctions
In humans and rodents, the frontal cortex is involved in
working memory, cognitive flexibility, attention and other
cognitive and executive functions that are affected in AD patients
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FIGURE 6 | β- and γ-secretase activities are not altered in the frontal cortex of TgMT5−/− mice compared to Tg. (A) Plots showing no differences of
β-secretase activity in solubilized membranes from WT, Tg and TgMT5−/−, using a specific fluorogenic substrate. (B) Western blot analysis (left) and quantification
(right) of the N-terminal fragment of PS1 (PS1-NTF), resulting from PS1 autocatalysis, in solubilized membranes of the frontal cortex. Tubulin-normalized values are
the mean ± SEM of 5–6 mice per genotype. ∗∗P < 0.01, between Tg and WT and #P < 0.05, between WT and TgMT5−/−, ANOVA followed by post hoc
(Continued)
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FIGURE 6 | Continued
Fisher’s LSD test. (C) Western blot analysis (upper) and quantification (lower)
of mature and immature nicastrin levels in solubilized membranes showing no
differences across groups. Tubulin-normalized values are the mean ± SEM of
5–6 mice per genotype. (D) Western blot analysis (left) and quantification
(right) of N-cadherin CTF levels in insoluble fractions showing no differences
across groups. GAPDH-normalized values are the mean ± SEM of 5–6 mice
per genotype. OD, optical density; A.U., arbitrary units. Vertical dashed lines
on western blots separate non-contiguous bands from the same gel.
(Baddeley et al., 1991; Brugger et al., 1996; Perry and Hodges,
1999). Many reports indicate that age between 4 and 6 months
is a transition period where the first behavioral deficits appear in
5xFAD mice, preceding the symptomatic phase of the pathology
(Oakley et al., 2006; Jawhar et al., 2012; Girard et al., 2013;
Baranger et al., 2016b). The OHM test was conceived to detect
dysfunctional cognitive plasticity in the frontal cortex of rodents
comparable to that observed in humans with lesions in the same
brain area (Del’Guidice et al., 2009; Verin et al., 1993). Like mice
with an injured frontal cortex, 4-month old 5xFADmice showed
an impaired ability to solve theOHMdelayed response paradigm,
which is concomitant with amyloidosis and gliosis (Girard
et al., 2013). Here, we demonstrated that frontal cortex-related
cognitive deficits of Tg mice were prevented in TgMT5−/−,
as it was the case for hippocampal-dependent spatial learning
and memory (Baranger et al., 2016b). Although spontaneous
locomotor activity was similar across genotypes, Tg mice showed
reduced anxiety compared to WT mice since they spent more
time in the center of the arena. This finding is in agreement with
previous observations made in older 5xFADmice using the same
paradigm (Jawhar et al., 2012). Interestingly, the natural anxiety
exhibited by rodents in open spaces was somehow recovered in
TgMT5−/− mice, whose behavior was closer to that of WT mice.
Overall, these data reinforce the idea of an early impairment
of executive functions in AD and highlight the role of the
frontal cortex in these cognitive processes. Our findings, also
stress the influence of MT5-MMP in the neurophysiological
mechanisms underlying different brain functions (e.g., working
memory, cognitive flexibility and long-term spatial memory), as
well as the efficacy of MT5-MMP modulation in improving such
functions.
Improved Learning Deficits Correlates with
the Amelioration of Pathological Stigmata
in TgMT5−/−
The striking reduction in amyloid burden and astrogliosis
observed in the frontal cortex of TgMT5−/− mice was
also observed in the neocortex and hippocampus (Baranger
et al., 2016b), supporting the idea that cognitive dysfunction
is tightly associated with biochemical and neuropathological
hallmarks present at specific spatio-temporal settings. Such
structural/functional correlation may be important for the
development of therapeutic strategies that target brain region-
associated behaviors. MT5-MMP deficiency reduced astrocyte
reactivity and GFAP levels, but microglial reactivity was
unaffected, in clear contrast with the reductions that affect
both cell types in the neocortex and hippocampi of TgMT5−/−
mice compared to Tg (Baranger et al., 2016b). It is noteworthy
that increased Iba1 immunoreactivity may not imply per se
a detrimental type I-like activation of microglia. On the
contrary, in this early stage of the pathology, an alternative
mode of microglial activation (i.e., type II) could contribute
to keep amyloid plaques in a compact rather than a diffuse
more pathogenic phenotype, as recently suggested in another
AD mouse model (Yuan et al., 2016). Diffuse amyloid
plaques have been also correlated with deficient synaptic
plasticity in the cortex of 5xFAD mice (Crouzin et al.,
2013). These data are consistent with the observation that
diffuse/compact amyloid plaque ratio was higher in frontal
cortices of Tg compared to TgMT5−/−. Another regional
difference in TgMT5−/− mice concerns the stable levels of
IL-1β in the frontal cortex, in contrast with the reductions
observed in the neocortex and hippocampus (Baranger et al.,
2016b). Alternatively, TNF-α levels were downregulated in
the frontal cortex of TgMT5−/− mice. Along this line,
MT5-MMP deficiency has also been linked with deficient
inflammatory response to TNF-α in the mouse PNS (Folgueras
et al., 2009). Together, these data reinforce the idea that
MT5-MMP may influence neuroinflammation in a cytokine-
and region-dependent manner. Although synaptic/neuronal
markers were preserved, this observation does not preclude
the existence of more subtle structural (e.g., shape/size of
dendritic spines) or electrophysiological modifications that
could account for changes in learning behavior. In line with
this idea, preserved synaptic markers in the hippocampus
of 4-month old 5xFAD mice (Oakley et al., 2006), are
concomitant with impaired LTP and spatial learning in these
mice (Kimura and Ohno, 2009; Baranger et al., 2016b; Tang et al.,
2016).
Changes in APP N-terminal and CTFs
Occur without Alterations of Secretase
Activity in TgMT5−/− Mice
Strong reductions of Aβ load suggested the possibility of
altered APP processing upon MT5-MMP deficiency, supported
by reduced levels of sAPPα and sAPPβ in bigenic mice
without changes of canonical APP. In line with previous
findings in the neocortex and hippocampus (Baranger et al.,
2016b), sAPP95 levels were reduced in TgMT5−/− brains. This
ectodomain fragment likely results from APP processing by
MT5-MMP ∼100 aminoacids upstream the β-site (between
Asn504 and Met505), as first described in vitro (Ahmad
et al., 2006), and also reported in the mouse brain below
98 kDa, using in this case an antibody raised against the
neoepitope generated by MT5-MMP (Willem et al., 2015).
Altogether, these data support the idea that neural APP is an
in vivo substrate of MT5-MMP. The significant reductions of
sAPPβ and its complementary membrane-bound C99 suggested
a possible decrease of BACE-1 activity upon MT5-MMP
deficiency, which would be consistent with lowered amyloidosis
exhibited by TgMT5−/− mice. However, this hypothesis was
infirmed by the stability of BACE-1 activity across genotypes
in ex vivo enzymatic assays using a synthetic substrate,
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FIGURE 7 | MT5-MMP promotes APP/Aβ distribution in early endosomes and increases Aβ levels in the supernatant of HEKswe cells.
(A) Representative epifluorescence microphotographs of HEKswe cells after transfection with green fluorescent protein (GFP) and MT5-MMP/GFP (MT5/GFP)
plasmids, showing from left to right: transferrin (Tf, green) labeling representing early endosomes, 6E10 immunostaining (red), the merge of both (Tf+6E10), where
yellow color represents colocalization. (B) Quantification of the colocalization between 6E10 and Tf. (C) Quantification of total 6E10 immunoreactivity.
(D) Quantification of Tf labeling. (E) Representative epifluorescence microphotographs of HEKswe cells transfected with GFP control or MT5/GFP plasmids. High
power magnification insets represent MT5/GFP or GFP (green), Tf (red) and the merge. Note partial colocalization of MT5/GFP and Tf in the merge panel (yellow color
and arrows); arrowheads point out MT5/GFP clusters that do not colocalize with Tf. The nucleus is stained with Hoechst (blue) (F) Quantification of the colocalization
between Aβ40/EEA1 (early endosomes), Aβ40/Rab11 (recycling endosomes) and Aβ40/Rab7 (late endosomes/lysosomes) in HEKswe after GFP or MT5/GFP
transfection. (G) Quantification of Aβ40 levels by ELISA assay in the supernatants of HEKswe cells showing a significant increase upon MT5/GFP transfection. The
increase in Aβ40 levels was prevented by γ-secretase inhibitor DAPT. Values for (B–D,F,G) are the mean ± SEM of four independent experiments. ∗∗P < 0.01,
∗∗∗P < 0.001; Student’s t test for (B–D,F). ∗P < 0.05, ANOVA followed by post hoc Fisher’s LSD test for (G). OD, optical density; A.U., arbitrary units.
indicating eventually that MT5-MMP deficiency did not affect
BACE-1 activity per se. We reached the same conclusion
with γ-secretase, as the autocatalytic activity of PS1 and the
processing of the N-cadherin CTF1 of 37 kDa were not altered
by MT5-MMP deficiency. Overall these data are in agreement
with our previous work in bigenic TgMT5−/− mice (Baranger
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et al., 2016b) and with the reported normal processing of
Notch (another γ-secretase substrate) in MT5-MMP deficient
mice in a non-AD context (Porlan et al., 2014). C99 levels
were sharply lowered in TgMT5−/− frontal cortices, in clear
contrast with the stability of C83 levels. This is a key
observation because C99 has been reported to be neurotoxic
on its own (Lauritzen et al., 2012) and its accumulation
precedes that of Aβ in the brain of 5xFAD (Py et al., 2014)
and 3xTg (Lauritzen et al., 2012) mice. In our conditions,
C99 accumulation in the frontal cortex of 4-month old
Tg mice is concomitant with higher levels of putative Aβ
trimers (∼12 kDa), considered as prominent neurotoxic Aβ
assemblies (Townsend et al., 2006; Larson and Lesné, 2012).
Alternatively, the size of this 6E10+ band is compatible with the
anticipated size of the recently reported N-terminally elongated
Aβ synaptotoxic fragment Aη-α generated in murine and
human neurons by combined η-secretase (i.e., MT5-MMP)
and α-secretase cleavage, and detected with an antibody raised
against the neoepitope generated by η-secretase at Asn504-
Met505 (Willem et al., 2015). It is noteworthy that in this
study, the brains of APPPS1-21 transgenic mice exhibited
hardly detectable levels of Aη-α, unlike Aη-β resulting from
combined action of η- and β-secretase. According to these
authors, these data would be consistent with the enhanced
BACE-1 affinity for the APP Swedish mutation carried by
APPPS1-21. Considering that 5xFAD mice also carry the
APP Swedish mutation, it would be plausible that the Aη-
α fragment accounts for minor immunoreactive signal of our
∼12 kDa 6E10+ band relative to other putative Aβ 6E10+
assemblies. This clearly excludes the Aη-β fragment, which
lacks the 6E10 epitope. Further investigations using ad hoc
tools, including antibodies that recognize the Aη-α N-terminal
neoepitope, will be necessary to determine whether this low
molecular weight band represents a mix of neurotoxic Aη-α and
Aβ assemblies (e.g., trimers), whose reduction is in any case
consistent with the amelioration of the pathological outcome in
TgMT5−/− mice.
MT5-MMP Promotes APP Trafficking in the
Endosomal Compartment
Trafficking of APP between the plasma membrane and the
intracellular compartments is increasingly considered as a pivotal
process for the understanding of amyloidogenesis and hence
the pathophysiology of AD (Rajendran and Annaert, 2012).
Extensive experimental evidence supports the view that APP
not cleaved by γ-secretase at the plasma membrane is rapidly
internalized and processed into C99 by BACE-1 in endosomes.
The latter provide the acidic microenvironment for optimal
BACE-1 function (Haass et al., 2012; Toh and Gleeson, 2016). In
these conditions, it is likely that 6E10+ immunostaining detected
in early endosomes mainly reveals the content of C99 and/or Aβ,
as previously suggested (Kaether et al., 2006b). The finding that
Aβ40 levels are also upregulated in these organelles supports the
idea that both C99 and Aβ coexist in the same compartment,
and implicitly, the same holds true for β- and γ-secretase. The
precise subcellular localization of β- and γ-secretases is still an
open debate, but growing evidence indicates that both may be
present in early endosomes (Rajendran and Annaert, 2012; Toh
and Gleeson, 2016). Importantly, our data strongly suggest that
after internalizationMT5-MMP and APP converge towards early
endosomes, in agreement with data reported for APP in various
cell types (Rajendran and Annaert, 2012; Toh and Gleeson,
2016) and with one report on MT5-MMP in native HEK cells
(Wang et al., 2004). Thus, early endosomes could be a privileged
subcellular locus of the pro-amyloidogenic interactions between
MT5-MMP and APP we described earlier (Baranger et al.,
2016b). In the context of MT5-MMP internalization, MT5-MMP
deficiency could have a higher impact on APP processing
by BACE-1 than by α-secretase, considering their preferential
endosomal and plasma membrane localization, respectively. It
remains to be investigated whether this might contribute to
the differences between C83 and C99 levels in TgMT5−/−
mice. In pace with the importance of proteolytic enzymes in
APP trafficking and amyloidogenesis, another APP-interacting
metalloproteinase, ADAM30, has been shown to promote
APP sorting to lysosomes and degradation (Letronne et al.,
2016).
In conclusion, the present work provides additional evidence
that MT5-MMP contributes to the pathophysiology of AD,
and that the underlying mechanisms include, at least in
part, the ability of the MMP to promote APP trafficking
into amyloidogenic pathways that remain to be thoroughly
investigated. The idea that interfering with MT5-MMP activity
and/or interactions improves the pathological outcome, supports
further validation of this proteinase as a novel promising AD
target.
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